Literature DB >> 17659774

Bone marrow mononuclear cells of MDS patients are characterized by in vitro proliferation and increased apoptosis independently of stromal interactions.

Lambert F R Span1, Eugenie Rutten, Anita Gemmink, Jan B M Boezeman, Reinier A P Raymakers, Theo de Witte.   

Abstract

Enhanced proliferation of MDS progenitors is abrogated by increased apoptosis of their progeny in vivo. We investigated whether bone marrow mononuclear cells (BMMNC) of MDS patients also showed enhanced proliferation and apoptosis in vitro in comparison with acute myeloid leukemia (AML) and normal BM (NBM). NBM showed a decrease in the number of clusters in time due to apoptosis of clusters and due to development of clusters into colonies with low apoptotic level. In MDS patients, about two-fold more clusters have developed at day 4, and in contrast with NBM, the total number of clusters at day 7 remained high in spite of an increasing percentage of apoptotic clusters (from 52 to 76%) in combination with more colony formation. The number of clusters and colonies showed a sharp decrease at day 10 because of persistently high apoptosis at cluster level and increasing apoptosis in colonies. BMMNC of AML patients showed a decreased proliferation with enhanced apoptosis at cluster level in contrast to a relatively low apoptotic levels in the colony-forming cells. This data show that increased proliferation is abrogated by enhanced apoptosis in MDS, whereas AML showed decreased proliferation with a low level of apoptosis in colony-forming cells. These growth profiles of BMMNC are independent of stromal influences and may represent intrinsic features of the MDS progenitors and accessory cell interactions.

Entities:  

Mesh:

Year:  2007        PMID: 17659774     DOI: 10.1016/j.leukres.2007.06.013

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  5 in total

1.  The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype.

Authors:  Ashley A Basiorka; Kathy L McGraw; Erika A Eksioglu; Xianghong Chen; Joseph Johnson; Ling Zhang; Qing Zhang; Brittany A Irvine; Thomas Cluzeau; David A Sallman; Eric Padron; Rami Komrokji; Lubomir Sokol; Rebecca C Coll; Avril A B Robertson; Matthew A Cooper; John L Cleveland; Luke A O'Neill; Sheng Wei; Alan F List
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

Review 2.  Genetics of progression from MDS to secondary leukemia.

Authors:  Andrew J Menssen; Matthew J Walter
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

3.  Unimpaired terminal erythroid differentiation and preserved enucleation capacity in myelodysplastic 5q(del) clones: a single cell study.

Authors:  Laurent Garderet; Ladan Kobari; Christelle Mazurier; Caroline De Witte; Marie-Catherine Giarratana; Christine Pérot; Norbert Claude Gorin; Hélène Lapillonne; Luc Douay
Journal:  Haematologica       Date:  2009-10-08       Impact factor: 9.941

4.  Impaired differentiation and apoptosis of hematopoietic precursors in a mouse model of myelodysplastic syndrome.

Authors:  Chul Won Choi; Yang Jo Chung; Christopher Slape; Peter D Aplan
Journal:  Haematologica       Date:  2008-07-04       Impact factor: 9.941

5.  Haploinsufficiency of Apc leads to ineffective hematopoiesis.

Authors:  Jianghong Wang; Anthony A Fernald; John Anastasi; Michelle M Le Beau; Zhijian Qian
Journal:  Blood       Date:  2010-01-11       Impact factor: 22.113

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.